You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 11, 2024

Regulatory Exclusivity:

✉ Email this page to a colleague

« Back to Dashboard

Drugs with Regulatory Exclusivity

Click here to exclude patents covering these drugs from this list

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	NDA	Approval Date	Type	Patent No.	Patent Expiration	Exclusivity Expiration	Patented / Exclusive Use
Mallinckrodt Ard	ACTHAR GEL	corticotropin	008372	Approved Prior to Jan 1, 1982	RX	⤷ Try a Trial	⤷ Try a Trial	⤷ Try a Trial	TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
Mallinckrodt Ard	ACTHAR GEL	corticotropin	008372	Approved Prior to Jan 1, 1982	RX	⤷ Try a Trial	⤷ Try a Trial	⤷ Try a Trial	TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
Mallinckrodt Ard	ACTHAR GEL	corticotropin	008372	Approved Prior to Jan 1, 1982	RX	⤷ Try a Trial	⤷ Try a Trial	⤷ Try a Trial	TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
Mallinckrodt Ard	ACTHAR GEL	corticotropin	008372	Approved Prior to Jan 1, 1982	RX	⤷ Try a Trial	⤷ Try a Trial	⤷ Try a Trial	TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
Mallinckrodt Ard	ACTHAR GEL	corticotropin	008372	Approved Prior to Jan 1, 1982	RX	⤷ Try a Trial	⤷ Try a Trial	⤷ Try a Trial	TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
>Applicant	>Tradename	>Generic Name	>NDA	>Approval Date	>Type	>Patent No.	>Patent Expiration	>Exclusivity Expiration	>Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.